2019 ARIA Care pathways for allergen immunotherapy

J Bousquet, O Pfaar, A Togias, HJ Schünemann, I Ansotegui, NG Papadopoulos, I Tsiligianni, I Agache, JM Anto, C Bachert, A Bedbrook, KC Bergmann, S Bosnic-Anticevich, I Bosse, J Brozek, M Calderon, G.W Canonica, L Caraballo, V Cardona, T Casale & 74 muut L Cecchi, DK Chu, E Costa, AA Cruz, W Czarlewski, SR Durham, G Du Toit, M Dykewicz, M Ebisawa, J.L Fauquert, M Fernandez-Rivas, WJ Fokkens, J Fonseca, JF Fontaine, R Gerth van Wijk, T Haahtela, S Halken, PW Hellings, D Ierodiakonou, T Iinuma, JC Ivancevich, L Jacobsen, M Jutel, I Kaidashev, M Khaitov, O Kalayci, J Kleine Tebbe, L Klimek, M L Kowalski, P Kuna, V Kvedariene, S La Grutta, D Larenas-Linemann, S Lau, D Laune, L Le, K Lodrup Carlsen, O Lourenço, HJ Malling, G Marien, E Menditto, G Mercier, J Mullol, A Muraro, R O'Hehir, Y Okamoto, GB Pajno, H.S Park, P Panzner, G Passalacqua, N Pham-Thi, G Roberts, C Rolland, N Rosario, D Ryan, B Samolinski, M Sanchez-Borges, G Scadding, M.H Shamji, A Sheikh, G.J Sturm, A Todo Bom, S Toppila-Salmi, M Valentin-Rostan, A Valiulis, E Valovirta, M.T Ventura, U Wahn, S Walker, D Wallace, S Waserman, A Yorgancioglu, T Zuberbier, The ARIA Working Group

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

Kuvaus

Abstract Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including health professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as on the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow up of patients. This article is protected by copyright. All rights reserved.
Alkuperäiskielienglanti
LehtiAllergy : European journal of allergy and clinical immunology
ISSN0105-4538
DOI - pysyväislinkit
TilaE-pub ahead of print - 7 huhtikuuta 2019
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

  • 3111 Biolääketieteet

Lainaa tätä

Bousquet, J., Pfaar, O., Togias, A., Schünemann, HJ., Ansotegui, I., Papadopoulos, NG., ... Group, T. ARIA. W. (2019). 2019 ARIA Care pathways for allergen immunotherapy. Allergy : European journal of allergy and clinical immunology. https://doi.org/10.1111/all.13805
Bousquet, J ; Pfaar, O ; Togias, A ; Schünemann, HJ ; Ansotegui, I ; Papadopoulos, NG ; Tsiligianni, I ; Agache, I ; Anto, JM ; Bachert, C ; Bedbrook, A ; Bergmann, KC ; Bosnic-Anticevich, S ; Bosse, I ; Brozek, J ; Calderon, M ; Canonica, G.W ; Caraballo, L ; Cardona, V ; Casale, T ; Cecchi, L ; Chu, DK ; Costa, E ; Cruz, AA ; Czarlewski, W ; Durham, SR ; Du Toit, G ; Dykewicz, M ; Ebisawa, M ; Fauquert, J.L ; Fernandez-Rivas, M ; Fokkens, WJ ; Fonseca, J ; Fontaine, JF ; van Wijk, R Gerth ; Haahtela, T ; Halken, S ; Hellings, PW ; Ierodiakonou, D ; Iinuma, T ; Ivancevich, JC ; Jacobsen, L ; Jutel, M ; Kaidashev, I ; Khaitov, M ; Kalayci, O ; Kleine Tebbe, J ; Klimek, L ; Kowalski, M L ; Kuna, P ; Kvedariene, V ; La Grutta, S ; Larenas-Linemann, D ; Lau, S ; Laune, D ; Le, L ; Carlsen, K Lodrup ; Lourenço, O ; Malling, HJ ; Marien, G ; Menditto, E ; Mercier, G ; Mullol, J ; Muraro, A ; O'Hehir, R ; Okamoto, Y ; Pajno, GB ; Park, H.S ; Panzner, P ; Passalacqua, G ; Pham-Thi, N ; Roberts, G ; Rolland, C ; Rosario, N ; Ryan, D ; Samolinski, B ; Sanchez-Borges, M ; Scadding, G ; Shamji, M.H ; Sheikh, A ; Sturm, G.J ; Todo Bom, A ; Toppila-Salmi, S ; Valentin-Rostan, M ; Valiulis, A ; Valovirta, E ; Ventura, M.T ; Wahn, U ; Walker, S ; Wallace, D ; Waserman, S ; Yorgancioglu, A ; Zuberbier, T ; Group, The ARIA Working. / 2019 ARIA Care pathways for allergen immunotherapy. Julkaisussa: Allergy : European journal of allergy and clinical immunology. 2019.
@article{da1a8a2723d34ad6b81843a81f2c2d63,
title = "2019 ARIA Care pathways for allergen immunotherapy",
abstract = "Abstract Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including health professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as on the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow up of patients. This article is protected by copyright. All rights reserved.",
keywords = "Allergen immunotherapy, asthma, rhinitis, children, stratification, mHealth, 3111 Biomedicine",
author = "J Bousquet and O Pfaar and A Togias and HJ Sch{\"u}nemann and I Ansotegui and NG Papadopoulos and I Tsiligianni and I Agache and JM Anto and C Bachert and A Bedbrook and KC Bergmann and S Bosnic-Anticevich and I Bosse and J Brozek and M Calderon and G.W Canonica and L Caraballo and V Cardona and T Casale and L Cecchi and DK Chu and E Costa and AA Cruz and W Czarlewski and SR Durham and {Du Toit}, G and M Dykewicz and M Ebisawa and J.L Fauquert and M Fernandez-Rivas and WJ Fokkens and J Fonseca and JF Fontaine and {van Wijk}, {R Gerth} and T Haahtela and S Halken and PW Hellings and D Ierodiakonou and T Iinuma and JC Ivancevich and L Jacobsen and M Jutel and I Kaidashev and M Khaitov and O Kalayci and {Kleine Tebbe}, J and L Klimek and Kowalski, {M L} and P Kuna and V Kvedariene and {La Grutta}, S and D Larenas-Linemann and S Lau and D Laune and L Le and Carlsen, {K Lodrup} and O Louren{\cc}o and HJ Malling and G Marien and E Menditto and G Mercier and J Mullol and A Muraro and R O'Hehir and Y Okamoto and GB Pajno and H.S Park and P Panzner and G Passalacqua and N Pham-Thi and G Roberts and C Rolland and N Rosario and D Ryan and B Samolinski and M Sanchez-Borges and G Scadding and M.H Shamji and A Sheikh and G.J Sturm and {Todo Bom}, A and S Toppila-Salmi and M Valentin-Rostan and A Valiulis and E Valovirta and M.T Ventura and U Wahn and S Walker and D Wallace and S Waserman and A Yorgancioglu and T Zuberbier and Group, {The ARIA Working}",
year = "2019",
month = "4",
day = "7",
doi = "10.1111/all.13805",
language = "English",
journal = "Allergy : European journal of allergy and clinical immunology",
issn = "0105-4538",
publisher = "Wiley",

}

Bousquet, J, Pfaar, O, Togias, A, Schünemann, HJ, Ansotegui, I, Papadopoulos, NG, Tsiligianni, I, Agache, I, Anto, JM, Bachert, C, Bedbrook, A, Bergmann, KC, Bosnic-Anticevich, S, Bosse, I, Brozek, J, Calderon, M, Canonica, GW, Caraballo, L, Cardona, V, Casale, T, Cecchi, L, Chu, DK, Costa, E, Cruz, AA, Czarlewski, W, Durham, SR, Du Toit, G, Dykewicz, M, Ebisawa, M, Fauquert, JL, Fernandez-Rivas, M, Fokkens, WJ, Fonseca, J, Fontaine, JF, van Wijk, RG, Haahtela, T, Halken, S, Hellings, PW, Ierodiakonou, D, Iinuma, T, Ivancevich, JC, Jacobsen, L, Jutel, M, Kaidashev, I, Khaitov, M, Kalayci, O, Kleine Tebbe, J, Klimek, L, Kowalski, ML, Kuna, P, Kvedariene, V, La Grutta, S, Larenas-Linemann, D, Lau, S, Laune, D, Le, L, Carlsen, KL, Lourenço, O, Malling, HJ, Marien, G, Menditto, E, Mercier, G, Mullol, J, Muraro, A, O'Hehir, R, Okamoto, Y, Pajno, GB, Park, HS, Panzner, P, Passalacqua, G, Pham-Thi, N, Roberts, G, Rolland, C, Rosario, N, Ryan, D, Samolinski, B, Sanchez-Borges, M, Scadding, G, Shamji, MH, Sheikh, A, Sturm, GJ, Todo Bom, A, Toppila-Salmi, S, Valentin-Rostan, M, Valiulis, A, Valovirta, E, Ventura, MT, Wahn, U, Walker, S, Wallace, D, Waserman, S, Yorgancioglu, A, Zuberbier, T & Group, TARIAW 2019, '2019 ARIA Care pathways for allergen immunotherapy' Allergy : European journal of allergy and clinical immunology. https://doi.org/10.1111/all.13805

2019 ARIA Care pathways for allergen immunotherapy. / Bousquet, J; Pfaar, O; Togias, A; Schünemann, HJ; Ansotegui, I; Papadopoulos, NG; Tsiligianni, I; Agache, I; Anto, JM; Bachert, C; Bedbrook, A; Bergmann, KC; Bosnic-Anticevich, S; Bosse, I; Brozek, J; Calderon, M; Canonica, G.W; Caraballo, L; Cardona, V; Casale, T; Cecchi, L; Chu, DK; Costa, E; Cruz, AA; Czarlewski, W; Durham, SR; Du Toit, G; Dykewicz, M; Ebisawa, M; Fauquert, J.L; Fernandez-Rivas, M; Fokkens, WJ; Fonseca, J; Fontaine, JF; van Wijk, R Gerth; Haahtela, T; Halken, S; Hellings, PW; Ierodiakonou, D; Iinuma, T; Ivancevich, JC; Jacobsen, L; Jutel, M; Kaidashev, I; Khaitov, M; Kalayci, O; Kleine Tebbe, J; Klimek, L; Kowalski, M L; Kuna, P; Kvedariene, V; La Grutta, S; Larenas-Linemann, D; Lau, S; Laune, D; Le, L; Carlsen, K Lodrup; Lourenço, O; Malling, HJ; Marien, G; Menditto, E; Mercier, G; Mullol, J; Muraro, A; O'Hehir, R; Okamoto, Y; Pajno, GB; Park, H.S; Panzner, P; Passalacqua, G; Pham-Thi, N; Roberts, G; Rolland, C; Rosario, N; Ryan, D; Samolinski, B; Sanchez-Borges, M; Scadding, G; Shamji, M.H; Sheikh, A; Sturm, G.J; Todo Bom, A; Toppila-Salmi, S; Valentin-Rostan, M; Valiulis, A; Valovirta, E; Ventura, M.T; Wahn, U; Walker, S; Wallace, D; Waserman, S; Yorgancioglu, A; Zuberbier, T; Group, The ARIA Working.

julkaisussa: Allergy : European journal of allergy and clinical immunology, 07.04.2019.

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

TY - JOUR

T1 - 2019 ARIA Care pathways for allergen immunotherapy

AU - Bousquet, J

AU - Pfaar, O

AU - Togias, A

AU - Schünemann, HJ

AU - Ansotegui, I

AU - Papadopoulos, NG

AU - Tsiligianni, I

AU - Agache, I

AU - Anto, JM

AU - Bachert, C

AU - Bedbrook, A

AU - Bergmann, KC

AU - Bosnic-Anticevich, S

AU - Bosse, I

AU - Brozek, J

AU - Calderon, M

AU - Canonica, G.W

AU - Caraballo, L

AU - Cardona, V

AU - Casale, T

AU - Cecchi, L

AU - Chu, DK

AU - Costa, E

AU - Cruz, AA

AU - Czarlewski, W

AU - Durham, SR

AU - Du Toit, G

AU - Dykewicz, M

AU - Ebisawa, M

AU - Fauquert, J.L

AU - Fernandez-Rivas, M

AU - Fokkens, WJ

AU - Fonseca, J

AU - Fontaine, JF

AU - van Wijk, R Gerth

AU - Haahtela, T

AU - Halken, S

AU - Hellings, PW

AU - Ierodiakonou, D

AU - Iinuma, T

AU - Ivancevich, JC

AU - Jacobsen, L

AU - Jutel, M

AU - Kaidashev, I

AU - Khaitov, M

AU - Kalayci, O

AU - Kleine Tebbe, J

AU - Klimek, L

AU - Kowalski, M L

AU - Kuna, P

AU - Kvedariene, V

AU - La Grutta, S

AU - Larenas-Linemann, D

AU - Lau, S

AU - Laune, D

AU - Le, L

AU - Carlsen, K Lodrup

AU - Lourenço, O

AU - Malling, HJ

AU - Marien, G

AU - Menditto, E

AU - Mercier, G

AU - Mullol, J

AU - Muraro, A

AU - O'Hehir, R

AU - Okamoto, Y

AU - Pajno, GB

AU - Park, H.S

AU - Panzner, P

AU - Passalacqua, G

AU - Pham-Thi, N

AU - Roberts, G

AU - Rolland, C

AU - Rosario, N

AU - Ryan, D

AU - Samolinski, B

AU - Sanchez-Borges, M

AU - Scadding, G

AU - Shamji, M.H

AU - Sheikh, A

AU - Sturm, G.J

AU - Todo Bom, A

AU - Toppila-Salmi, S

AU - Valentin-Rostan, M

AU - Valiulis, A

AU - Valovirta, E

AU - Ventura, M.T

AU - Wahn, U

AU - Walker, S

AU - Wallace, D

AU - Waserman, S

AU - Yorgancioglu, A

AU - Zuberbier, T

AU - Group, The ARIA Working

PY - 2019/4/7

Y1 - 2019/4/7

N2 - Abstract Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including health professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as on the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow up of patients. This article is protected by copyright. All rights reserved.

AB - Abstract Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including health professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as on the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow up of patients. This article is protected by copyright. All rights reserved.

KW - Allergen immunotherapy

KW - asthma

KW - rhinitis

KW - children

KW - stratification

KW - mHealth

KW - 3111 Biomedicine

U2 - 10.1111/all.13805

DO - 10.1111/all.13805

M3 - Article

JO - Allergy : European journal of allergy and clinical immunology

JF - Allergy : European journal of allergy and clinical immunology

SN - 0105-4538

ER -

Bousquet J, Pfaar O, Togias A, Schünemann HJ, Ansotegui I, Papadopoulos NG et al. 2019 ARIA Care pathways for allergen immunotherapy. Allergy : European journal of allergy and clinical immunology. 2019 huhti 7. https://doi.org/10.1111/all.13805